http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#Head
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#assertion
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#provenance
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#pubinfo
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#assertion
http://purl.obolibrary.org/obo/DOID_8552
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_8552
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB08901
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association
http://www.w3.org/2000/01/rdf-schema#label
iclusig ponatinib is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with t315i positive cml chronic phase accelerated phase or blast phase or t315i positive philadelphia chromosome positive acute lymphoblastic leukemia ph all iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with t315i positive cml chronic phase accelerated phase or blast phase or t315i positive philadelphia chromosome positive acute lymphoblastic leukemia ph all 1 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml 5 7 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml see warnings and precautions 5 7
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB08901
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#provenance
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#pubinfo
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#sig
http://purl.org/nanopub/x/hasSignature
gbjZSswwLDxFeq8RkbUz7+V/FmsEPK6IcPPDcHfqYV5DtsO6O8lnIvBBX/wgd32VByPr92bBWEmyPLJjdCzvrmMSN9cExKDd/MfD0MVR22eAf6woFzwZ0hQE2SN8QlaDFmL0+/CRBpNuNHweQt5kIaF9u2nW4O5/VbRJktU/ro0=
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY
http://purl.org/dc/terms/created
2021-07-03T14:30:54.514+02:00
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs